Ziopharm Oncology, Inc. has signed a definitive agreement to acquire indibulin, a novel synthetic anti-cancer agent that targets mitosis, from affiliates of Baxter Healthcare Corp. Indibulin is available as both an oral and a nanosuspension intravenous (IV) form with the oral form in a Phase I trial and the nanosuspension in late preclinical. Indibulin, now designated as ZIO-301, may offer efficacy, dosing and toxicity advantages as compared to marketed taxanes, including paclitaxel (Taxol), pac...